LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 1 STUDY

被引:1
作者
Mcinnes, I. [1 ]
Kato, K. [2 ]
Magrey, M. [3 ]
Merola, J. F. [4 ,5 ]
Kishimoto, M. [6 ]
Haaland, D. [7 ,8 ]
Chen, L. [2 ]
Duan, Y. [2 ]
Liu, J. [2 ]
Lippe, R. [9 ]
Wung, P. [2 ]
机构
[1] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow, Scotland
[2] AbbVie Inc, Immunol, N Chicago, IL USA
[3] Case Western Reserve Univ, Cleveland, OH 44106 USA
[4] Brigham & Womens Hosp, Boston, MA 02115 USA
[5] Harvard Med Sch, Dermatol & Rheumatol, Boston, MA 02115 USA
[6] Kyoto Univ, Sch Med, Dept Nephrol & Rheumatol, Tokyo, Japan
[7] McMaster Univ, Hamilton, ON, Canada
[8] Waterside Clin, Rheumatol & Clin Immunol Allergy, Barrie, ON, Canada
[9] AbbVie Deutschland GmbH Co KG, Immunol, Wiesbaden, Germany
关键词
D O I
10.1136/annrheumdis-2022-eular.799
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
POS0081
引用
收藏
页码:260 / 261
页数:2
相关论文
共 1 条
[1]   Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study [J].
McInnes, Iain B. ;
Kato, Koji ;
Magrey, Marina ;
Merola, Joseph F. ;
Kishimoto, Mitsumasa ;
Pacheco-Tena, Cesar ;
Haaland, Derek ;
Chen, Liang ;
Duan, Yuanyuan ;
Zueger, Patrick ;
Liu, John ;
Lippe, Ralph ;
Pangan, Aileen L. ;
Behrens, Franck .
RMD OPEN, 2021, 7 (03)